Phase II Study of the Histone Deacetylase Inhibitor PXD101 for the Treatment of Myelodysplastic Syndrome

Trial Profile

Phase II Study of the Histone Deacetylase Inhibitor PXD101 for the Treatment of Myelodysplastic Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2014

At a glance

  • Drugs Belinostat (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jul 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov (NCT01647009).
    • 19 Jul 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov (NCT01647009).
    • 19 Jul 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov (NCT01647009).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top